The US Centers for Disease Control and Prevention announced that studies have begun to use a vaccine against the monkeypox virus in the country. The vaccine is planned to be used in ‘high-risk’ contacts.
After the coronavirus, which created a new fear of epidemic in the world, monkeypox virushas been seen in 16 different countries so far. While it is observed that the cases continue to increase especially in Western Europe, US President Joe Biden’s “Everyone should be worriedThe statement also increased the attention to the virus.
Today, there has been an extremely important development in the United States regarding the monkeypox virus. US Centers for Disease Control and Prevention (CDC)announced that the monkeypox vaccine in the country’s Strategic National Stock will be put into use against the monkeypox virus, which is increasingly seen in the country.
Jynneos vaccine to be used in high-risk patients
CDC’s Dr. Jennifer McQuiston shared in her statement, “Some of the first patients for high-risk contacts From National Stock Jynneos vaccine I can report that there is a request for its release, it is currently actively taking place.” he said. McQuiston explained that the United States also has a good stock of vaccines as it prepares for the possibility of needing doses for smallpox.
The aforementioned Jynneos vaccine was licensed in the USA to prevent smallpox and especially monkeypox. According to information provided by McQuiston, the country is currently with over 1,000 doses and the company began to supply more doses to the USA. Another licensed vaccine that can be used to prevent monkeypox, ACAM2000, is in the country. More than 100 million doses was declared.
RELATED NEWS
What is the New Deadly Epidemic ‘Monkey Flower’, What Symptoms Does It Show, What Precautions Should Be Taken to Protect it?
RELATED NEWS